Suppr超能文献

阑尾切除术与右半结肠切除术治疗分化良好的 T1 阑尾腺癌的肿瘤学效果相当。

Appendectomy Is Oncologically Equivalent to Right Hemicolectomy for Well-Differentiated T1 Appendiceal Adenocarcinoma.

机构信息

Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

出版信息

Dis Colon Rectum. 2023 Jan 1;66(1):67-74. doi: 10.1097/DCR.0000000000002089. Epub 2022 Aug 18.

Abstract

BACKGROUND

Right hemicolectomy is recommended for appendiceal adenocarcinoma but may not be needed for early stage disease.

OBJECTIVE

This study aimed to determine whether appendectomy offers adequate oncologic outcomes for T1 appendiceal adenocarcinoma from a national cohort of patients.

DESIGN

Patients with T1 appendiceal adenocarcinoma (mucinous and nonmucinous histology) treated with either a right hemicolectomy or appendectomy between 2004 and 2016 were retrieved. Multivariate Cox regression analysis was used to identify predictors of overall survival.

SETTING

The study was conducted using a national cancer database.

PATIENTS

A total of 320 patients (median age, 62 y; 47% women) were identified: 69 (22%) underwent an appendectomy and 251 (78%) underwent a right hemicolectomy.

MAIN OUTCOME MEASURE

Overall survival was measured.

RESULTS

Nonmucinous adenocarcinoma was identified in 194 (61%), whereas 126 (39%) had mucinous adenocarcinoma. Of the overall cohort, 43% had well-differentiated histology, 39% had moderately differentiated disease, and 4% had poorly differentiated tumors. The rate of lymph node metastasis was lower in well-differentiated tumors (3%) compared with moderately (10%) or poorly differentiated tumors (25%). On univariate survival analysis, right hemicolectomy was associated with improved 1-, 3-, and 5-year overall survival in patients with moderately/poorly differentiated disease ( p < 0.001) but not for well-differentiated disease ( p = 1.000). After adjustment, right hemicolectomy was associated with overall survival improvement for moderately/poorly differentiated T1 adenocarcinoma (HR = 0.26 [95% CI, 0.08-0.82]; p = 0.02) but not for well-differentiated disease.

LIMITATIONS

This study was limited by its retrospective nature.

CONCLUSIONS

The current analysis from the National Cancer Database demonstrates that appendectomy is associated with equivalent survival to right hemicolectomy for well-differentiated T1 adenocarcinoma, whereas for moderately and poorly differentiated disease, right hemicolectomy is oncologically superior to appendectomy. See Video Abstract at http://links.lww.com/DCR/B689 .

LA APENDICECTOMA ES ONCOLGICAMENTE EQUIVALENTE A LA HEMICOLECTOMA DERECHA PARA EL ADENOCARCINOMA APENDICULAR T BIEN DIFERENCIADO

ANTECEDENTES:La hemicolectomía derecha se recomienda para el adenocarcinoma apendicular, pero puede no ser necesaria para la enfermedad en estadio temprano.OBJETIVO:Este estudio tuvo como objetivo determinar si la apendicectomía ofrece resultados oncológicos adecuados para el adenocarcinoma apendicular T1 de una cohorte nacional de pacientes.DISEÑO:Se recuperaron pacientes con adenocarcinoma apendicular T1 (histología mucinoso y no mucinoso) tratados con hemicolectomía derecha o apendicectomía entre 2004-2016. Se utilizó un análisis de regresión de Cox multivariante para identificar los predictores de la supervivencia global.ENTORNO CLÍNICO:Base de datos nacional sobre cáncer.PACIENTES:Se identificaron un total de 320 pacientes (mediana de edad 62 años, 47% mujeres): 69 (22%) se sometieron a una apendicectomía y 251 (78%) se sometieron a una hemicolectomía derecha.PRINCIPAL MEDIDA DE RESULTADO:Sobrevida global.RESULTADOS:Se identificó adenocarcinoma no mucinoso en 194 (61%) mientras que 126 (39%) tenían adenocarcinoma mucinoso. De la cohorte general, el 43% tenía una histología bien diferenciada, el 39% tenía una enfermedad moderadamente diferenciada y el 4% tenía tumores poco diferenciados. La tasa de metástasis en los ganglios linfáticos fue menor en los tumores bien diferenciados (3%) en comparación con los tumores moderadamente (10%) o pobremente diferenciados (25%). En el análisis de sobrevida univariante, la hemicolectomía derecha se asoció con una mejor sobrevida general a 1, 3, y 5 años en pacientes con enfermedad moderada / pobremente diferenciada ( p < 0,001) pero no para la enfermedad bien diferenciada ( p = 1,000). Después del ajuste, la hemicolectomía derecha se asoció con una mejora de la sobrevida general para el adenocarcinoma T1 moderadamente / poco diferenciado (HR = 0,26, IC del 95%: 0,08-0,82, p = 0,02) pero no para la enfermedad bien diferenciada.LIMITACIONES:Este estudio estuvo limitado por su naturaleza retrospectiva.CONCLUSIONES:El análisis actual de la base de datos nacional de cáncer demuestra que la apendicectomía se asocia con una sobrevida similar a la hemicolectomía derecha para el adenocarcinoma T1 bien diferenciado, mientras que para la enfermedad moderada y pobremente diferenciada, la hemicolectomía derecha es oncológicamente superior a la apendicectomía. Consulte Video Resumen en http://links.lww.com/DCR/B689 . (Traducción-Dr. Yazmin Berrones-Medina ).

摘要

背景

阑尾腺癌推荐行右半结肠切除术,但对于早期疾病可能不需要。

目的

本研究旨在从全国患者队列中确定 T1 阑尾腺癌患者行阑尾切除术是否可获得足够的肿瘤学结果。

设计

检索 2004 年至 2016 年间接受阑尾切除术或右半结肠切除术治疗的 T1 阑尾腺癌(黏液性和非黏液性组织学)患者。采用多变量 Cox 回归分析确定总生存期的预测因素。

设置

本研究使用国家癌症数据库进行。

患者

共确定 320 例患者(中位年龄 62 岁;47%为女性):69 例(22%)行阑尾切除术,251 例(78%)行右半结肠切除术。

主要观察指标

总生存期。

结果

194 例(61%)为非黏液性腺癌,126 例(39%)为黏液性腺癌。在总队列中,43%为高分化组织学,39%为中分化疾病,4%为低分化肿瘤。高分化肿瘤的淋巴结转移率较低(3%),中分化(10%)或低分化(25%)肿瘤较高。在单因素生存分析中,中/低分化肿瘤患者的右半结肠切除术与 1 年、3 年和 5 年的总生存率提高相关( p < 0.001),但高分化疾病患者的总生存率提高( p = 1.000)。调整后,中/低分化 T1 腺癌患者的右半结肠切除术与总生存率提高相关(HR = 0.26[95%CI:0.08-0.82]; p = 0.02),但高分化疾病患者无相关性。

局限性

本研究受到其回顾性性质的限制。

结论

国家癌症数据库的当前分析表明,对于高分化 T1 腺癌,阑尾切除术与右半结肠切除术的生存结果相当,而对于中/低分化疾病,右半结肠切除术在肿瘤学上优于阑尾切除术。

相似文献

1
Appendectomy Is Oncologically Equivalent to Right Hemicolectomy for Well-Differentiated T1 Appendiceal Adenocarcinoma.
Dis Colon Rectum. 2023 Jan 1;66(1):67-74. doi: 10.1097/DCR.0000000000002089. Epub 2022 Aug 18.
7
Multiple High-Risk Features for Stage II Colon Carcinoma Portends Worse Survival Than Stage III Disease.
Dis Colon Rectum. 2023 Aug 1;66(8):1076-1084. doi: 10.1097/DCR.0000000000002425. Epub 2022 Feb 28.
8
Patient Survival With ypT0N+ Following Neoadjuvant Therapy in Rectal Cancer.
Dis Colon Rectum. 2022 Oct 1;65(10):1224-1231. doi: 10.1097/DCR.0000000000002186. Epub 2022 May 24.
9
Lymph Node Mapping in Transverse Colon Cancer Treated Using Laparoscopic Colectomy With D3 Lymph Node Dissection.
Dis Colon Rectum. 2022 Mar 1;65(3):340-352. doi: 10.1097/DCR.0000000000002108.
10
Oncological Outcomes of Transanal Endoscopic Surgery for the Surgical Management of T2 and T3 Rectal Cancer.
Dis Colon Rectum. 2023 Jul 1;66(7):1012-1021. doi: 10.1097/DCR.0000000000002617. Epub 2023 Mar 6.

引用本文的文献

1
Predictors of Recurrence in Nonmetastatic Appendiceal Epithelial Cancers: An Updated Single-Center Experience Over 25 Years.
Ann Surg Oncol. 2025 Feb;32(2):695-702. doi: 10.1245/s10434-024-16366-7. Epub 2024 Nov 27.
2
ASO Author Reflections: Predictors of Recurrence in Non-metastatic Appendiceal Epithelial Cancers-The Role of Staging Right Colectomy.
Ann Surg Oncol. 2025 Feb;32(2):713-714. doi: 10.1245/s10434-024-16479-z. Epub 2024 Nov 21.
5
Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma.
ESMO Open. 2023 Oct;8(5):101619. doi: 10.1016/j.esmoop.2023.101619. Epub 2023 Aug 24.
6
Which is the appropriate surgical procedure for appendiceal adenocarcinoma: appendectomy, partial colectomy or right hemicolectomy?
Clin Transl Oncol. 2024 Jan;26(1):297-307. doi: 10.1007/s12094-023-03259-6. Epub 2023 Jun 27.
7
Low-Risk Non-mucinous Adenocarcinoma of the Appendix: When Is an Appendectomy Enough?
Ann Surg Oncol. 2022 Apr;29(4):2144-2145. doi: 10.1245/s10434-021-11229-x. Epub 2022 Jan 10.

本文引用的文献

1
Predictors of lymph node metastases in patients with mucinous appendiceal adenocarcinoma.
J Surg Oncol. 2020 Sep;122(3):399-406. doi: 10.1002/jso.25963. Epub 2020 Apr 28.
2
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms.
Ann Surg Oncol. 2020 Jun;27(6):1753-1760. doi: 10.1245/s10434-020-08316-w. Epub 2020 Apr 13.
4
Role of right hemicolectomy in patients with low-grade appendiceal mucinous adenocarcinoma.
Am J Surg. 2019 Dec;218(6):1239-1243. doi: 10.1016/j.amjsurg.2019.07.035. Epub 2019 Jul 25.
5
A Predictive Model for Nodal Metastases in Patients With Appendiceal Cancers.
Ann Surg. 2021 Jul 1;274(1):155-161. doi: 10.1097/SLA.0000000000003501.
6
Discordant Diagnostic Terminology and Pathologic Grading of Primary Appendiceal Mucinous Neoplasms Reviewed at a High-Volume Center.
Ann Surg Oncol. 2019 Aug;26(8):2607-2614. doi: 10.1245/s10434-019-07447-z. Epub 2019 May 20.
7
Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade.
World J Gastrointest Oncol. 2017 Sep 15;9(9):354-362. doi: 10.4251/wjgo.v9.i9.354.
8
The Management and Prognostic Prediction of Adenocarcinoma of Appendix.
Sci Rep. 2016 Dec 16;6:39027. doi: 10.1038/srep39027.
9
When and When Not to Perform a Right Colon Resection with Mucinous Appendiceal Neoplasms.
Ann Surg Oncol. 2017 Mar;24(3):729-732. doi: 10.1245/s10434-016-5632-2. Epub 2016 Oct 21.
10
Management of Appendix Cancer.
Clin Colon Rectal Surg. 2015 Dec;28(4):247-55. doi: 10.1055/s-0035-1564433.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验